ArticleScientific reports2025
Explore the key genes and prognosis related to mitochondrial permeability transition driving necrosis gene in kidney renal clear cell carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitochondrial permeability transition (MPT)-driven necrosis is associated with kidney renal clear cell carcinoma (KIRC), but its role in prognosis remains unclear. This study develops a prognostic model for KIRC outcomes using MPT-driven necrosis-related genes (MPTDNRGs). Differentially expressed genes (DEGs) from TCGA-KIRC samples were analyzed and categorized based on MPTDNRGs scores. Three key genes-IL2RA, CD7, and CXCL13-were identified as significant prognostic markers and used to construct a risk model, validated through public datasets and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The risk score and age were the independent prognostic factors. A nomogram incorporating these factors demonstrated good clinical utility. The high-risk group was enriched in immune-related pathways, such as systemic lupus erythematosus, while the low-risk group showed enrichment in metabolism-related pathways, including butanoate metabolism. Significant differences in 25 immune cells were observed between the risk groups, with the high-risk group exhibiting higher TIDE scores, suggesting a greater likelihood of immune escape. Additionally, a ceRNA network revealed complex interactions, such as CXCL13-hsa-miR-670-5p-AL121985.1, and predicted 25 transcription factors for key MPTDNRGs. This study presents a novel prognostic model for KIRC based on three MPTDNRGs, offering valuable insights into KIRC prognosis and potential therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.